Cost effectiveness analysis of ceftriaxone with cefoperazon in thypoid patients at x mataram hospital

  • Sondang Khairani Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Pancasila, Jakarta, 12640, Indonesia
  • Reise Manninda Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Pancasila, Jakarta, 12640, Indonesia
  • Akhmad Fajri Widodo Graduate Institute of Injury Prevention and Control, Cpllege of Public Hea;th Taipei Medical University, Taiwan
  • Lalu Joko Raharjo Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Pancasila, Jakarta, 12640, Indonesia
DOI: https://doi.org/10.35814/jifi.v22i1.1585

Abstract

Typhoid is the third most common cause of hospitalisation in Indonesia, affecting 100,000 people every year. Typhoid fever, with an average case fatality rate of 2.45% at X Mataram Hospital, was among the top 10 most common inpatient illnesses in 2019 and 2020. Antibiotics are effective in reducing typhoid infection, lowering body temperature, shortening the length of hospitalisation, and reducing mortality. The aim study to determine the cost-effectiveness of using ceftriaxone and cefoperazone antibiotics for typhoid patients at X Mataram Hospital. Method a compares two groups of antibiotics and evaluates direct costs and clinical outcomes clinic (length of stay and time free of fever). This research is using ACER's cost-effectiveness analysis. The study included 63 samples with an average direct cost of Rp 3,645,106 for cefoperazon and Rp 3,168,106 for ceftriaxone. According to the ACER analysis results, hospitalisation with ceftriaxone is more cost-effective a lower cost of Rp 704,023 and based on fever-free time, cefoperazone is more cost-effective at Rp. 1,024,094. No correlation between antibiotic effectiveness and fever-free time, no correlation between antibiotic effectiveness and length of hospitalisation (p-value >0.05).

References

[1] I. E. Purba, T. Wandra, N. Nugrahini, S. Nawawi, N. Kandun, “Typhoid Fever Control Program in Indonesia: challenges and opportunities,” Health Research and Development Media: Media Litbangkes, vol 26, no. 2, pp. 99-108, 2016.

[2] W. H. Organization. Typhoid and other invasive salmonellosis, pp 1–13, 2018.

[3] Ministry of Health Indonesia, “Basic Health Research,” Agency for Health Research and Development. Jakarta, 2018.

[4] P. Hazmen, S. Kumala, P. Sarnianto. “Analysis of Typhoid Fever Treatment Costs Based on Clinical Pathway at Harapan Bunda Hospital”. J Profesi Med J Kedokt dan Kesehatan, vol 13, no. 2, pp. 74–81, 2019.

[5] S. Alba, M.I. Bakker, M. Hatt, P.F.D. Scheelbeek, R. Dwiyanti, R. Usman, et al. “Risk factors of typhoid infection in the Indonesian archipelago,” PLoS One, vol. 11, no. 6, pp. 1-14, 2016. Available from: http://www.cdkjournal.com/index.php/CDK/article/view/1255.

[6] Y. P. Cita. “Salmonella typhi bacteria and typhoid fever,” Jurnal Kesehatan Masyarakat Andalas, vo. 6, no.1, pp. 6-42, 2011.

[7] R. Karunakaran, S. T. Tay, F. F. Rahim, B. B. Lim, I. C. Sam, M. K. Bador, H. Hassan, S. D. Puthucheary, “Ceftriaxone resistance and genes encoding extended-spectrum β-lactamase among nontyphoidal Salmonella species from a tertiary care hospital in Kuala Lumpur, Malaysia,” Japanese journal of infectious diseases, vol. 65, no. 5, pp. 5-433, 2012.

[8] M. Z. Rustam, “Relationship between patient characteristics and the incidence of typhoid fever in inpatients at Salewangan Maros Regional Hospital,” STRADA Jurnal Ilmiah Kesehatan, vol. 1, no. 2. Pp. 57-62, 2012.

[9] T. M. Andayani, “Pharmacoeconomics: Principles and Methodology,” Bursa Ilmu, Yogyakarta. 2013.

[10] I. G. N. D. Sukmawati, M. K. A. Jaya, D. A. Swastini, “Evaluation of the Use of Antibiotics in Inpatient Typhoid Patients at One of the Bali Provincial Government Hospitals using the Gyssens and ATC/DDD Methods,” J Med
Udayana, vol. 9, no. 1, pp. 37–44, 2020.

[11] B. G. Katzung, T. W. Vanderah TW. “Basic & clinical pharmacology,” 15th ed. New York McGraw-Hill; 2018.

[12] P. B. S. Kinanta, D.G. D. D. Santhi, A. N. N. Subawa, “Profile of antibiotic administration and clinical improvement of fever in pediatric patients with typhoid fever at Sanglah General Hospital, Denpasar,” J Med Udayana, vol. 9, no. 3, pp. 4-10, 2020.

[13] S. Sidabutar, H. I. Satari, “Empirical Treatment Options for Typhoid Fever in Children: Chloramphenicol or Ceftriaxone?,” Sari Pediatri, vol. 11, no.6, 2010.

[14] C. D. Britto, V. K. Wong, G. Dougan, A. J. Pollard, “A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid,” PLoS Negl Trop Dis, vol. 12, no. 10, pp. 1-15,
2018.

[15] M. Ardiaria, “Epidemiology of Clinical Manifestations and Management of Typhoid Fever,” Journal of Nutrition and health, vol. 7, no.2, 2019.

[16] H. Puspasari, D. Suryaningrat, M. Rizky, “Cost Analysis of Treatment for Patients Diagnosed with Typhoid Fever at the Inpatient Installation of Dr Soedarso Pontianak Hospital in 2018,”J Farm Dan Ilmu Kefarmasian Indonesia, vol. 1, no. 1, 2020.

[17] P. R. Melarosa, D. K. Ernawati, A. N. Mahendra, “Pattern of Antobiotic Use in Adult Patients with Thypoid fever at Sanglah Hospital Denpasar,” E-Jurnal Med Udayana, vol. 8, no.2, 2019.

[18] Ministry of Health Indonesia, “Guidelines for the Implementation of Pharmacoeconomic Assessment,” Jakarta: Ministry of Health Indonesia, 2013.

[19] S. N. Hidayah, A. Hakim, A. Syahrir, W. Anggraini, “Cost Effectiveness Analysis of Seftriaxone and Sefotaxime in Typhoid Fever Patients in the Shofa and Marwah PKU Karangasem Muhammadiyah Paciran Inpatient Installation in 2019,” J Islam Pharm, vol. 5, no. 2, pp. 46-52, 2020.

[20] C. N. Thompson, A. Karkey, S. Dongol, A. Arjyal, M. Wolbers, T. Darton, et al, “Treatment response in enteric fever in an era of increasing antimicrobial resistance: An individual patient data analysis of 2092 participants enrolled into 4 randomized, controlled trials in Nepal,” Clin Infect Dis, vol. 64, no. 11, pp. 31-1522, 2017.

[21] D. Oktavia, L. Indriani, M. Dewi, “Evaluation of the Administration of Antibiotics to Thypoid Fever patients in the Inpatient Installation of Azra Hospital Bogor,” FITOFARMAKA J Ilm Farm, vol. 10, no. 1, pp. 54-64, 2020.

[22] A. Lorensia, D.D. Queljoe, M. Dwike, “Cost-Effectiveness Analysis of Chloramphenicol and Ceftriaxone for the Treatment of Typhoid Fever in Adult Patients at Sanglah Hospital, Denpasar,” Media Pharm Indonesia, vol. 2, no. 2, 2018.

[23] S. Khoiriyah, K. Lestari, “Artikel review: Pharmacoeconomic Assessment Underpinning Treatment Selection ini Indonesia.” Farmaka, vol 16, pp. 45-134, 2018.
Published
2024-04-30
How to Cite
KHAIRANI, Sondang et al. Cost effectiveness analysis of ceftriaxone with cefoperazon in thypoid patients at x mataram hospital. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 22, n. 1, p. 56-62, apr. 2024. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1585>. Date accessed: 21 may 2024. doi: https://doi.org/10.35814/jifi.v22i1.1585.
Citation Formats
Issue
Vol 22 No 1 (2024): JIFI In Press
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.